Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Fibrinogen Catabolism in Patients with Type II and Type IV Hyperlipidemia

Fibrinogen Catabolism in Patients with Type II and Type IV Hyperlipidemia Fibrinogen catabolism was studied by plasma fibrinogen chromatography and other methods in 99 subjects with hyperlipoproteinemla Types lla, Mb, and IV, and in 24 control subjects with normal blood llpid values. Subjects with either a history of thromboembolic vascular disease or clinical evidence of atherosclerosis were excluded. Type II subjects (I.e., the combined group of Type lla and lib subjects) showed an elevation of plasma high molecular weight fibrinogen complexes, which Is indicative of enhanced fibrin formation. They also showed an elevation of fibrinogenflrst-derivatlve, which Is Indicative of fibrinogenolysls and Increased plasma euglobulin activity. Subjects with Type IV hyperlipoproteinemla showed similar findings to those of Type II except that high molecular weight fibrinogen complex concentration was normal. Subsequently, 36 patients received a fat-controlled, low cholesterol diet and were studied In a blind, random, crossover study of dietary vs clofibrate treatment. Although total cholesterol and triglyceride levels fell significantly during the treatment periods, chromatographlc findings of abnormal plasma fibrinogen remained unchanged. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis Wolters Kluwer Health

Fibrinogen Catabolism in Patients with Type II and Type IV Hyperlipidemia

Loading next page...
 
/lp/wolters-kluwer-health/fibrinogen-catabolism-in-patients-with-type-ii-and-type-iv-iQNXVeSGm7
Copyright
© 1981 by American Heart Association, Inc.
ISSN
0276-5047

Abstract

Fibrinogen catabolism was studied by plasma fibrinogen chromatography and other methods in 99 subjects with hyperlipoproteinemla Types lla, Mb, and IV, and in 24 control subjects with normal blood llpid values. Subjects with either a history of thromboembolic vascular disease or clinical evidence of atherosclerosis were excluded. Type II subjects (I.e., the combined group of Type lla and lib subjects) showed an elevation of plasma high molecular weight fibrinogen complexes, which Is indicative of enhanced fibrin formation. They also showed an elevation of fibrinogenflrst-derivatlve, which Is Indicative of fibrinogenolysls and Increased plasma euglobulin activity. Subjects with Type IV hyperlipoproteinemla showed similar findings to those of Type II except that high molecular weight fibrinogen complex concentration was normal. Subsequently, 36 patients received a fat-controlled, low cholesterol diet and were studied In a blind, random, crossover study of dietary vs clofibrate treatment. Although total cholesterol and triglyceride levels fell significantly during the treatment periods, chromatographlc findings of abnormal plasma fibrinogen remained unchanged.

Journal

ArteriosclerosisWolters Kluwer Health

Published: May 1, 1981

There are no references for this article.